Release date- 28082019 - Houston - Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell
redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.
Immatics, a biopharma company developing T-cell
redirecting cancer immunotherapies, announced a strategic collaboration and option agreement with Celgene to develop novel adoptive cell therapies targeting multiple cancers.
Summary: This report analyzes the current and future scenario of the global T-cell
Acute Lymphoblastic Leukemia Market.
Fate Therapeutics and MSK are conducting research and development of T-cell
product candidates derived from iPSCs.
M2 PRESSWIRE-July 31, 2019-: The World T-Cell
Immunotherapies Market (2019-2030): Market Lanscape, Key Insights, Clinical Trial Analysis, Therapy Profiles, Emerging Technologies, Case Studies
[USPRwire, Mon Jul 15 2019] This report analyzes the current and future scenario of the global T-cell
Acute Lymphoblastic Leukemia Market .
WAR IN THE BLOOD Sun 9pm BBC2 Having exhausted all other treatments for his leukaemia, Graham Threader agreed to join the first human trial of CAR T-cell
therapy - hailed as a major breakthrough in cancer treatment.
Chronic HBV infection is associated with impaired virus-specific T-cell
M2 PHARMA-April 2, 2019-Imbrium Therapeutics Gains US FDA Orphan Drug Designation for Tinostamustine for the Treatment of T-cell
The findings, published in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell